No record found


* Returns not adjusted for payouts
Company Profile
Ferozsons Laboratories Limited was incorporated as a private limited company on 28 January 1954 and was converted into a public limited company on 08 September 1960. The Company is primarily engaged in the imports, manufacture and sale of pharmaceutical products and medical devices.
Mr. Osman Khalid Waheed | CEO |
Mrs. Akhter Khalid Waheed | Chairperson |
Mr. Syed Ghausuddin Saif | Company Secretary |
Ferozsons Laboratories Limited 197-A, The Mall Rawalpindi, Pakistan.
CorpTec Associates (Pvt.) Limited, 503-E, Johar Town, Lahore
KPMG Taseer Hadi & Co. Chartered Accountants
June
Equity Profile
Announcements
Date | Title | Document |
---|---|---|
Apr 28, 2023 | Transmission of Quarterly Report for the Period Ended 2023-03-31 | View PDF |
Apr 27, 2023 | Financial Results for the Quarter Ended 2023-03-31 | View PDF |
Mar 1, 2023 | Transmission of Quarterly Report for the Period Ended 2022-12-31 | View PDF |
Feb 27, 2023 | Financial Results for the Quarter Ended 2022-12-31 | View PDF |
Oct 28, 2022 | Transmission of Quarterly Report for the Period Ended 2022-09-30 | View PDF |
Oct 24, 2022 | Financial Results for the Quarter Ended 2022-09-30 | View PDF |
Sep 9, 2022 | Transmission of Annual Report for the Year Ended 2022-06-30 | View PDF |
Aug 31, 2022 | Financial Results for the Year Ended 2022-06-30 | View PDF |
May 6, 2022 | Transmission of Quarterly Report for the Period Ended 2022-03-31 | View PDF |
Apr 26, 2022 | Financial Results for the Quarter Ended 2022-03-31 | View PDF |
Date | Title | Document |
---|---|---|
Jun 5, 2023 | Notice of Extraordinary General Meeting | View PDF |
Jun 2, 2023 | Notice of Extraordinary General Meeting prior to publication | View PDF |
May 29, 2023 | Emergent Board Meeting 30-05-2023 | View |
Apr 20, 2023 | Board Meeting | View |
Feb 20, 2023 | Board Meeting | View |
Nov 17, 2022 | Presentation of Trades in the Board of Directors Meeting executed by the Directors, CEO, or Executives of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Nov 16, 2022 | Presentation of Trades in the Board of Directors Meeting executed by the Directors, CEO, or Executives of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Oct 14, 2022 | Board Meeting | View |
Sep 30, 2022 | Certified True Copy of Resolutions Passed in the 66th Annual General Meeting of the Company | View PDF |
Sep 9, 2022 | Notice of Annual General Meeting | View PDF |
Sep 9, 2022 | Notice of Annual General Meeting prior to publication | View PDF |
Aug 24, 2022 | Board Meeting | View |
Jul 29, 2022 | Board Meeting Other Than Financial Results | View |
Date | Title | Document |
---|---|---|
May 31, 2023 | Material Information | View PDF |
May 18, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Jan 13, 2023 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Oct 14, 2022 | Corporate Briefing Session | View PDF |
Oct 12, 2022 | Disclosure of Interest by a Director CEO, or Executive of a listed company and their Spouses and the Substantial Shareholders u/c 5.6.1.(d) of PSX Regulations | View |
Oct 11, 2022 | Dispatch of Bonus Share Certificate and Credit of Bonus Shares in CDS | View PDF |
Oct 11, 2022 | Credit/Dispatch of Bonus Share Certificates | View |
Oct 10, 2022 | Credit of Final Cash Dividedn | View |
Sep 2, 2022 | Issue of Bonus Shares | View PDF |
Sep 1, 2022 | Issue fo Bonus Shares | View PDF |
Oct 20, 2021 | Corporate Briefing Session | View PDF |
Financials
All numbers in thousands (000's) except EPS
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Sales | 7,806,414 | 7,033,622 | 5,394,043 | 5,180,804 |
Profit after Taxation | 514,149 | 725,235 | 395,655 | 251,046 |
EPS | 14.19 | 20.02 | 10.92 | 8.32 |
Q3 2023 | Q2 2023 | Q1 2023 | Q3 2022 | |
---|---|---|---|---|
Sales | 2,688,405 | 2,319,318 | 2,286,495 | 2,173,038 |
Profit after Taxation | 24,437 | 94,222 | 104,918 | 239,896 |
EPS | 0.56 | 2.17 | 2.41 | 5.52 |

Ratios
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Gross Profit Margin (%) | 45.06 | 41.04 | 41.12 | 39.49 |
Net Profit Margin (%) | 6.59 | 10.31 | 7.34 | 4.85 |
EPS Growth (%) | (29.12) | 83.33 | 31.25 | 163.29 |
PEG | (0.65) | 0.21 | 0.88 | 0.08 |
Payouts
Date | Financial Results | Details | Book Closure |
---|---|---|---|
August 31, 2022 3:53 PM | 30/06/2022(YR) | 50% (D) - 20% (B) | 23/09/2022 - 30/09/2022 |
August 31, 2021 12:24 PM | 30/06/2021(YR) | 100%(F) (D) | 24/09/2021 - 30/09/2021 |
September 24, 2020 3:07 PM | 30/06/2020(YR) | 40%(F) (D) - 20% (B) | 17/10/2020 - 26/10/2020 |
September 23, 2019 2:47 PM | 30/06/2019(YR) | 40%(F) (D) | 18/10/2019 - 25/10/2019 |
February 25, 2019 12:50 PM | 31/12/2018(HYR) | 20% (i) (D) | 08/03/2019 - 14/03/2019 |
September 25, 2018 3:08 PM | 30/06/2018(YR) | 20% (D) | 20/10/2018 - 27/10/2018 |
August 30, 2017 3:38 PM | 30/06/2017(YR) | 40% (D) | M /10/2017 - 18/10/2017 |
January 30, 2017 3:47 PM | 31/12/2016(HYR) | 30%(I) (D) | 11/02/2017 - 19/02/2017 |
August 30, 2016 10:16 AM | 30/06/2016(YR) | 120% (F) (D) | 11/10/2016 - 20/10/2016 |
January 26, 2016 9:54 AM | 31/12/2015(HYR) | 100%(I) (D) | 20/02/2016 - 26/02/2016 |